Coherus Oncology, Inc.
CHRS
$1.42
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 46.88M | 42.17M | 37.16M | 31.64M | 31.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.88M | 42.17M | 37.16M | 31.64M | 31.68M |
| Cost of Revenue | 14.98M | 13.81M | 12.52M | 11.53M | 9.94M |
| Gross Profit | 31.91M | 28.36M | 24.64M | 20.11M | 21.74M |
| SG&A Expenses | 92.98M | 95.90M | 104.50M | 109.80M | 111.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.03M | 218.61M | 215.70M | 214.80M | 208.98M |
| Operating Income | -167.15M | -176.43M | -178.54M | -183.16M | -177.30M |
| Income Before Tax | -172.66M | -183.12M | -182.87M | -185.95M | -195.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -172.66 | -183.12 | -182.87 | -185.95 | -195.94 |
| Earnings from Discontinued Operations | 358.93M | 351.15M | 337.84M | 365.70M | 65.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 186.27M | 168.02M | 154.97M | 179.75M | -130.94M |
| EBIT | -167.15M | -176.43M | -178.54M | -183.16M | -177.30M |
| EBITDA | -163.39M | -172.51M | -174.48M | -178.52M | -172.49M |
| EPS Basic | 1.67 | 1.46 | 1.33 | 1.54 | -1.13 |
| Normalized Basic EPS | -0.87 | -0.95 | -0.98 | -1.01 | -0.99 |
| EPS Diluted | 1.67 | 1.46 | 1.33 | 1.54 | -1.13 |
| Normalized Diluted EPS | -0.87 | -0.95 | -0.98 | -1.01 | -0.99 |
| Average Basic Shares Outstanding | 489.07M | 468.53M | 463.58M | 462.56M | 461.31M |
| Average Diluted Shares Outstanding | 489.07M | 468.53M | 463.58M | 462.56M | 461.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |